drugset
drugset / Trial / NCT06577259

Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants

NCT06577259 ↗

Phase 1 Completed 25 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess the relative bioavailability of BMS-986435 tablet formulations in healthy adult male and female participants.

Timeline

Start
2024-09-03
Primary completion
2025-02-19
Completion
2025-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject DELOCAMTEN Small molecule — —

Indications

No indication recorded.